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with command hallucinations (COMMAND): a randomised 
controlled trial
Max Birchwood, Maria Michail, Alan Meaden, Nicholas Tarrier, Shon Lewis, Til Wykes, Linda Davies, Graham Dunn, Emmanuelle Peters
Summary
Background Acting on command hallucinations in psychosis can have serious consequences for the individual and 
for other people and is a major cause of clinical and public concern. No evidence-based treatments are available to 
reduce this risk behaviour. We therefore tested our new cognitive therapy to challenge the perceived power of 
voices to inﬂ ict harm on the voice hearer if commands are not followed, thereby reducing the hearer’s motivation 
to comply.
Methods In COMMAND, a single-blind, randomised controlled trial, eligible participants from three centres in the 
UK who had command hallucinations for at least 6 months leading to major episodes of harm to themselves or other 
people were assigned in a 1: 1 ratio to cognitive therapy for command hallucinations + treatment as usual versus just 
treatment as usual for 9 months. Only the raters were masked to treatment assignment. The primary outcome was 
harmful compliance. Analysis was by intention to treat. The trial is registered, number ISRCTN62304114.
Findings 98 (50%) of 197 participants were assigned to cognitive therapy for command hallucinations + treatment as 
usual and 99 (50%) to treatment as usual. At 18 months, 39 (46%) of 85 participants in the treatment as usual group 
fully complied with the voices compared with 22 (28%) of 79 in the cognitive therapy for command hallucinations + 
treatment as usual group (odds ratio 0·45, 95% CI 0·23–0·88, p=0·021). At 9 months the treatment eﬀ ect was not 
signiﬁ cant (0·74, 0·40–1·39, p=0·353). However, the treatment by follow-up interaction was not signiﬁ cant and the 
treatment eﬀ ect common to both follow-up points was 0·57 (0·33–0·98, p=0·042).
Interpretation This is the ﬁ rst trial to show a clinically meaningful reduction in risk behaviour associated with 
commanding voices. We will next determine if change in power was the mediator of change. Further more complex 
trials are needed to identify the most inﬂ uential components of the treatment in reducing power and compliance.
Funding UK Medical Research Council and the National Institute for Health Research.
Introduction
Schizophrenia aﬀ ects 0·8% of the UK population, 
usually starts in young adults, and, in some cases, leads 
to persistent disability.1 Individuals with this illness have 
a high risk of suicide (8%) and deliberate self-harm and, 
although the risk is small, they are more likely to 
perpetrate aggression than are those without 
schizophrenia.2 Individuals acting on delusions, 
including commanding voices, are a cause for concern at 
societal and political levels because members of the 
public are at risk of apparently random acts of violence, 
even when the perpetrators are well supported by 
services. These concerns are shown in national policy 
documents—eg, the UK national mental health strategy 
aims to reduce avoidable harm to self or others.3
Although drug and other treatments have improved, 
nearly 50% of individuals will have treatment-resistant 
symptoms or symptoms arising from non-adherence to 
drug regimens.4,5
Auditory hallucinations are some of the most prominent 
and distressing of the treatment-resistant symptoms, and 
command hallucinations are the most high risk of 
these.6 Shawyer and colleagues6 reported a median 
53% prevalence of command hallucinations in adult 
participants with psychiatric disorders; 48% of these 
participants said the commands stipulated harmful or 
dangerous actions, rising to 69% for participants in 
medium secure units.7
However, the link between the presence of command 
hallucinations and harm to self or others is not 
straightforward. In the MaCarthur study,8 no association 
was reported between the presence of delusions or 
command hallucinations and violence. Thoughts about 
violence, however, were a strong predictor of violence 
6 months later.
Our cognitive model of voices has clariﬁ ed that it is not 
only the level of activity of voices, or indeed their content, 
that drives aﬀ ect and behaviour, but also the nature of 
the relationship with the personiﬁ ed voice.9–11 We showed 
that compliance or appeasement behaviour can occur 
when the hearer believes the voice to have malevolent 
intent, and crucially to have the power to deliver the 
threat.9 These ﬁ ndings have been independently 
replicated in a forensic population.12
This theoretical framework informed the development 
of a cognitive behaviour therapy: cognitive therapy for 
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command hallucinations, which was designed to weaken 
and challenge beliefs about the power of voices, enabling 
the individual to break free of the need to comply or 
appease and thereby reduce harmful compliance 
behaviour and distress.13,14 This therapeutic model was 
developed because of a major gap in the evidence base. 
Although cognitive behaviour therapy is recommended 
by the UK’s National Institute for Health and Care 
Excellence15 to reduce overall symptom severity, the 
guidance notes that there is insuﬃ  cient evidence for 
voice compliance and frequency and inconsistent 
evidence for any direct eﬀ ect on delusions.
We tested the model in a proof-of-principle trial16 in a 
group at high risk of compliance with commands 
because of recent (<9 months) harmful compliance or 
appeasement. This operational deﬁ nition of risk was 
associated with a 39% rate of recurrence of harmful 
compliance within 12 months in the control group; in 
people receiving the therapy, the rate of compliance 
dropped to 14%, equivalent to an eﬀ ect size of 1·1. This 
drop was accompanied by a reduction in the perceived 
power of the voice; there was a reduction in delusional 
distress and depression, but this was not maintained at 
12 months’ follow-up. Crucially, as expected, no change 
was noted in the frequency or intensity of voices, but 
only in the (power) relation with them. The results of a 
similar trial by Shawyer and colleagues17 of a diﬀ erent 
therapy based on acceptance of voices by “cultivating the 
capacity to just notice voices and associated thoughts 
rather than believe and act on them” showed no eﬀ ect on 
compliance or other outcomes. However, this study had a 
low base rate of compliance.
The aim in the COMMAND trial was to assess the 
acceptability, eﬀ ectiveness, and cost-eﬀ ectiveness of 
cognitive therapy for command hallucinations. The 
primary hypothesis was that in participants with 
command hallucinations who have recently acted on the 
voices and are therefore at high risk of doing so again 
cognitive therapy for command hallucinations would 
increase resistance and thereby reduce the level of 
further harmful compliance behaviour and the 
associated risk. Secondary hypotheses were that the 
perceived power of the persecuting voice would be 
reduced, which would act as the mediator of change in 
compliance; there would be no changes in the frequency 
or topography of voices; and cognitive therapy for 




This was a single-blind, prospective, pragmatic 
randomised controlled trial for the comparison of 
cognitive therapy for command hallucinations + 
treatment as usual with treatment as usual alone.18 
Eligible participants were recruited for the trial from 
three UK centres in Birmingham (which included a site 
in Leicester), London, and Manchester. Recruitment to 
the trial began in February, 2008, and was completed in 
July, 2010. Follow-up assessments began in November, 
2008, and were completed in January, 2012. Treatment 
was for 9 months and follow-up was at 9 months and 
18 months after randomisation.
The West Midlands Research Ethics Committee (number 
06/MRE07/71) provided ethics approval for the study.
Participants were eligible if they met the following 
criteria: had International Statistical Classiﬁ cation of 
Diseases and Related Health Problems, 10th Revision 
(ICD-10), schizophrenia, schizoaﬀ ective (F20, 22, 23, 
25, 28, 29), or mood disorders (F32),19 and were under 
the care of a clinical team; were aged 16 years and older; 
had a history of harmful command hallucinations for at 
least 6 months with recent (<9 months) history of harm 
to self or others, or major social transgressions as a 
result of the commands (full or incomplete compliance); 
or had harmful command hallucinations whereby the 
individual was distressed and appeasing the powerful 
voice.
Exclusion criteria were organic impairment or primary 
diagnosis of addictive disorder or insuﬃ  cient command 
of English.
Eligible participants were identiﬁ ed by clinical studies 
oﬃ  cers from the UK Mental Health Research Network 
who reviewed electronic case records for history of 
auditory hallucinations and evidence of risky, aggressive, 
and violent behaviour. Trained researchers did a 
screening interview with each participant to conﬁ rm 
eligibility for the trial. After the screening interview, 
eligible participants were invited to take part and asked to 
provide informed consent. Once written informed 
consent had been obtained, the researchers administered 
a battery of assessments and on completion participants 
were randomly allocated either to the cognitive therapy 
for command hallucinations + treatment as usual group 
or to the treatment as usual only group.
Randomisation and masking
Participants were randomly assigned to the cognitive 
therapy command hallucinations + treatment as usual 
group or the treatment as usual only group in a 1:1 ratio 
using an allocation sequence generated with 
OpenCDMS.25 and were stratiﬁ ed by the centre with 
permuted blocks with a randomly varying block size after 
stratiﬁ cation by centre. OpenCDMS then sent an email 
notiﬁ cation of the allocation to the therapists and trial 
manager. After randomisation, an email notiﬁ cation 
about group allocation was sent to the trial manager, trial 
administrator, and therapists. An email notiﬁ cation 
conﬁ rming that the participant had been randomly 
assigned to treatment (with no information about group 
allocation) was sent to the centre research assistant. The 
trial administrator then sent a letter to the participant 
and the care coordinator informing them about the 
outcome of the randomisation. Thus, the results of the 
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randomisation were masked from the assessors and 
randomisation was independent.
Many strategies were used to assure masked ratings, 
including research workers who were not involved in the 
randomisation process; therapists were required to 
consider potential breaks in masking when planning 
room use and diary arrangements; and participants were 
reminded by assessors not to disclose treatment allocation. 
Overall, 19 (10%) breaks in masking were reported (four in 
the treatment as usual only group and 15 in the cognitive 
therapy for command hallucinations + treatment as usual 
group) of 197 participants. When masking was broken, 
another rater, masked to group assignment, assessed and 
rated the participant for all subsequent assessments; 
accordingly, all ﬁ nal ratings were masked.
Interventions
In cognitive therapy for command hallucinations, 
cognitive behaviour therapy techniques are used to 
assess and modify conviction in four beliefs linked to the 
construct of voice power: the voice has absolute power 
and control; the individual must comply or appease or be 
severely punished; the identity of the voice (eg, the Devil); 
and the meaning attached to the voice (eg, the individual 
is being punished for a past misdemeanour).
Our protocol for cognitive therapy for command 
hallucinations was developed by MB and details are 
provided in our casebook manuals.13,14 The essence of the 
therapy is to test the perceived power of the voice by 
assessment of evidence for the omniscience of the voice, 
the apparent ability of the voice to predict the future and 
deliver its threats, and the voice hearer’s perceived lack of 
control over the voice. All trial therapists (qualiﬁ ed clinical 
psychologists at National Health Service [NHS] band 8a 
and accredited cognitive therapists) received about 30 h of 
structured training led by MB and AM. Recordings of 
cognitive therapy for command hallucinations with pretrial 
participants were rated according to the cognitive therapy 
checklist (below). Therapists recording high adherence to 
cognitive therapy received their ﬁ rst randomly assigned 
participant. All therapists were highly adherent to cognitive 
therapy for command hallucinations. Although the 
intervention is protocol based, diﬀ erences are recognised 
in voice content, and beliefs about voices and compliance. 
Cognitive therapy for command hallucinations diﬀ ers 
from previous and generic types and models of cognitive 
behaviour therapy for psychosis. First, it is informed by a 
well validated theoretical framework, which can be used to 
predict an individual’s compliance with voices and the 
associated distress rather than the presence of psychotic 
symptoms. Second, it adheres to a staged process informed 
by our cognitive model. Third, the model proposes a single 
variable that is the target of therapy and also the 
hypothesised mediator: the power diﬀ erential between the 
voice and the hearer of the voice.
The intervention was delivered in NHS clinics with 
outreach to participants’ homes by nine cognitive 
therapists who were supervised in each centre by a lead 
clinician with expertise in cognitive behaviour therapy 
for psychosis. Therapists delivered the intervention only 
to the cognitive therapy for command hallucinations + 
treatment as usual group. Group supervision at sites was 
done once a fortnight with videoconference to monitor 
adherence to protocol and to minimise centre diﬀ erences 
in implementation. Adherence to protocol was monitored 
with our adapted version of the Cognitive Therapy 
Checklist18 using cases selected at random by the trial 
manager. Acceptability was assessed indirectly by 
monitoring the rate of treatment completion and 
dropout; a qualitative method, which will be reported in a 
further paper, was used.18 Cognitive therapy for command 
hallucinations was administered over a maximum of 
9 months (about 25 sessions of therapy).
Treatment as usual was provided by community mental 
health and assertive outreach and early intervention 
teams. Treatment as usual including antipsychotic 
medication was documented in accordance with the trial 
protocol derived from our pilot study.18
Outcomes
The compliance or resistance was assessed at baseline 
(over the previous 9 months), then at 9 months and 
18 months after the start of treatment with the Voice 
Compliance Scale (VCS).18 This scale is a categorical scale 
that requires a thorough interview in accordance with the 
Cognitive Assessment of Voices schedule to obtain a 
detailed record of all voices and emotional and 
behavioural responses towards them; and interviewing 
and using information from, where available, at least one 
other informant (carers, hostel worker, care coordinator, 
or psychiatrist). In all cases, care records were scrutinised 
to search for documented behaviours that were 
suggestive of compliance. If there was discrepancy 
between self and informant report that would change a 
rating, we recorded the more severe level of compliance. 
This method yields speciﬁ c behaviours that are 
assembled into a summary and classiﬁ ed as neither 
appeasement nor compliance; symbolic appeasement, 
including mental rehearsal or compliance with 
innocuous or harmless commands; actual appeasement 
(ie, preparatory acts or gestures); partial compliance with 
at least one severe command; and full compliance with at 
least one severe command. For each of these behaviours, 
deﬁ nitions and examples were provided.
29 VCS interviews were selected and rated in a masked 
fashion by MM for the presence versus absence of full 
compliance, with an overall κ of 0·73. VCS was assessed 
for reliability in our pilot trial16 with similar results to 
those in this main trial.
The primary outcome was full compliance, assessed 
after completion of cognitive therapy for command 
hallucinations (highest score 5).
Secondary outcomes were also assessed. The Voice 
Power Diﬀ erential (VPD) Scale10 was used to measure the 
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perceived power diﬀ erential between voice and voice 
hearer. Score range was 7–35, with higher scores 
indicating greater power diﬀ erential in favour of the 
voices. This scale has good internal reliability (Cronbach’s 
α=0·85) with high 1 week retest reliability (r=0·82). The 
ﬁ rst item on the scale, the overall power diﬀ erential 
between voice and voice hearer, was analysed separately 
in keeping with our protocol and underlying theory (my 
voice is much more powerful than me vs my voice is 
much less powerful than me).
The Personal Knowledge Questionnaire and 
Omniscience Scale10 was used to measure the hearer’s 
beliefs about the voice’s knowledge about personal 
information (eg, the voice knows everything about me 
and my past). The score range was 0–15.
The Beliefs About Voices Questionnaire-Revised 
(BAVQ-R)20 was used to assess key beliefs about the 
omnipotence and intentions of the voices, whether bene-
volent or malevolent, and the emotional and behavioural 
reactions of the participants towards their voices 
(resistance vs engagement). The scale consists of ﬁ ve 
subscales: malevolence (score range 0–18), benevolence 
(0–18), omnipotence (0–18), resistance (0–27), and 
engagement (0–24). The scale has good test–retest 
(r=0·89) and internal reliability (Cronbach’s α=0·85) and 
is widely used for research into hallucinations.
Distress associated with voices was assessed with the 
Psychotic Symptoms Rating Scales (PSYRATS), Auditory 
Hallucinations (PSYRATS-AH) subscale.21 Score range 
on this subscale was 0–44, with higher scores indicating 
increasing severity. The items amount of distress and 
amount of negative content (range 0–4 for both items) 
are also reported separately. The scale has excellent 
psychometric properties with good inter-rater reliability 
for the auditory hallucinations section (range 0·78–1·00).
The Calgary Depression Rating Scale for 
Schizophrenia22 is a widely used nine-item observer-rated 
measure speciﬁ cally designed for schizophrenia, mini-
mising contamination with negative symptoms and the 
extrapyramidal side-eﬀ ects of antipsychotic medication. 
Score range is 0–27, with higher scores indicating greater 
severity. The Beck Hopelessness Scale23 is used to assess 
feelings about the future, loss of motivation, and 
expectations; score range is 0–20, with higher scores 
indicating greater hopelessness. The Beck Scale for 
Suicidal Ideation allows a thorough assessment of 
suicidal intent; score range is 0–38, with higher scores 
indicating an increase in suicidal risk.
The Positive and Negative Syndrome Scale (PANSS)24 
includes scales of positive symptoms (score range 7–49), 
negative symptoms (7–49), and general psychopathology 
(16–112); it is used widely in schizophrenia research. The 
items hallucinations and delusions (1–7 for each item) 
are also reported separately.
All prescribed antipsychotic medications at baseline and 
18 months were recorded and converted to daily dose of 
olanzapine equivalents, with tables from the International 
Consensus Study of Antipsychotic Dosing.25 All adverse 
events were recorded on standard proforma, at each of the 
sites, signed oﬀ  by MB, and collated for the trial data 
monitoring and ethics committee and the ethics 
committee.
Statistical analysis
Analysis was by intention to treat. The planned 
recruitment to the trial was based on a sample size of 
100 individuals per group having a greater than 80% 
power to detect an absolute diﬀ erence between a 
proportion who have acted on their voices (VCS score=5) 
of 40% under treatment as usual group and 20% in the 
cognitive therapy for command hallucinations group 
with a Pearson χ² test with two-tailed signiﬁ cance of 
0·05.
All analyses were done with Stata (version 12). The 
primary outcome was evaluated with an intention-to-
treat analysis with a logistic regression to allow measure-
ment of centre membership and baseline compliance on 
the VCS. A likelihood-based random eﬀ ects (intercepts) Figure: Trial proﬁ le
98 allocated to cognitive therapy for 
command hallucinations group
86 received allocated intervention
12 did not receive allocated intervention
1 died
8 refused or not interested
3 moved out of area or could not be 
contacted
99 allocated to treatment as usual group
434 excluded
407 did not meet inclusion criteria
27 declined to participate
676 patients assessed for eligibility
197 randomly assigned
242 eligible 
98 included in intention-to-treat analysis 99 included in intention-to-treat analysis
18 lost to follow-up at 18 months
3 died
6 refused




    1 died
    5 refused or not interested
    1 moved out of area
15 lost to follow-up at 18 months
11 refused
3 moved out of area or could 
not be contacted
1 unwell
45 declined or could not be contacted 
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model was used to simultaneously estimate treatment 
eﬀ ects at both the 9-month and 18-month follow-up 
assessments and to allow for missing follow-up data that 
are assumed to be missing at random. Analogous 
random-eﬀ ects models were used for the analysis of the 
quantitative secondary outcomes. All models included a 
centre-by-time interaction and a centre-by-baseline-
covariate interaction. Any data within a questionnaire 
scale were prorated with the mean of the remaining 
items unless there were more than 5% missing data, in 
which case the scale was designated as missing (this did 
not apply to VCS)
Because data were from only two follow-up timepoints, 
no assumptions were needed about the autocorrelation 
of the longitudinal data. The estimated measures in the 
initial model included a main eﬀ ect of treatment and an 
eﬀ ect of treatment-by-time interaction; when there was 
no evidence of an eﬀ ect of treatment-by-time interaction, 
the model was simpliﬁ ed by removing the interaction to 
estimate a treatment eﬀ ect that was common to both 
follow-up timepoints.
The trial is registered, number ISRCTN62304114.
Role of the funding source
The design of the trial was peer reviewed by the funders 
and amended accordingly. The funders had no role in the 
gathering, analysis, or interpretation of the data, nor in 
the writing of the paper. MB, GD, and MM had access to 
the raw data. The corresponding author had full access to 
all of the data and the ﬁ nal responsibility to submit for 
publication.
Results
The ﬁ gure shows the trial proﬁ le. 676 participants were 
screened for eligibility and of these 407 (60%) did not 
meet the inclusion criteria and 27 (4%) declined to 
participate. 242 (36%) participants were eligible to 
participate in the study and 197 (81%) of these were 
randomly assigned. 45 (19%) individuals declined or 
could not be contacted after the baseline assessment, 
before randomisation. Recruitment was completed in 
July, 2010. The ﬁ nal sample size was 197 participants 
(64 from Birmingham, 23 Leicester, 62 London, and 
48 Manchester), with 98 participants allocated to the 
cognitive therapy for command hallucinations + 
treatment as usual group and 99 to the treatment as 
usual group. 165 (84%) participants were rated as being 
fully compliant and 32 (16%) as partly compliant or 
appeasing on VCS at baseline.
164 (83%) of 197 participants completed the 18-month 
follow-up assessment, 17 (9%) refused to complete the 
assessment, 11 (6%) could not be contacted, three (2%) 
died, and two (1%) were unwell. The clinical diagnoses in 
the sample of 197 participants were schizophrenia (98 
[50%]), schizoaﬀ ective disorder (29 [15%]), paranoid 
schizophrenia (17 [9%]), psychosis (50 [25%]), and bipolar 
disorder (three [2%]). 88 (45%) participants had hospital 
admissions in the previous 18 months, including 27 (31%) 
that were compulsory under the UK Mental Health Act. 
Table 1 shows the diﬀ erent services used by the participants 
in the 18 months before randomisation. Conversion to 
olanzapine equivalents was done for 136 (69%) of 197 
participants; in 61 (31%) cases, dose was not available or 
could not be converted. The mean dose of all prescribed 
antipsychotics, expressed as olanzapine equivalents, was 
25·79 mg/day (SD 21·73), including 38 (28%) of 
136 participants receiving more than 30 mg/day: 
26·88 mg/day (22·02) in the cognitive therapy for 
command hallucinations + treatment as usual group and 
24·77 mg/day (21·55) in the treatment as usual group. At 
18 months, the dose was 19·34 mg/day (14·30) in the 
Cognitive therapy for 
command hallucinations + 
treatment as usual group 
(n=98)
Treatment as usual 
group (n=99)
Inpatient hospital services 53 56
Acute psychiatric ward 45 50
Psychiatric rehabilitation ward 2 3
Long stay psychiatric ward 3 3
Emergency or crisis centre 5 9
General medical ward 14 13
Alcohol or drug treatment ward 0 1
Other 3 5
Hospital outpatient services 82 86
Psychiatric 74 67
Hospital alcohol or substance service 3 4
Non-psychiatric 4 5
Accident and emergency 20 18
Day hospital 4 7
Other 10 15
Community-based services 55 58
Community mental health centre 37 33
Day care centre 18 15
Group therapy 7 3
Sheltered workshop 2 2
Specialist education 3 3
Other 20 24
Primary and community care services 98 98
Family doctor 80 89
Psychiatrist 81 82
Psychologist 13 21
Alcohol or drug treatment or rehabilitation service 14 10
District nurse 3 8
Community psychiatric nurse or case manager 79 80
Social worker 27 26
Occupational therapist 18 21
Voluntary counsellor 1 1
Home help or care worker 15 11
Other 65 63
Data are numbers. *Participants received more than one service.
Table 1: Service use in the 18 months before randomisation*
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cognitive therapy for command hallucinations + treatment 
as usual group and 19·99 mg/day (14·32) in the treatment 
as usual group. 115 (58%) of 197 participants received one 
antipsychotic drug, 61 (31%) received two, and nine (5%) 
three or more; we were unable to ﬁ nd the medication data 
for the remaining participants. 32 (16%) of 197 participants 
were prescribed clozapine at baseline: 16 (50%) in the 
cognitive therapy for command hallucinations + treatment 
as usual group and 16 (50%) in the treatment as usual 
group.
Table 2 shows the nature of the commands heard by 
participants and the high risk of harmful behaviours 
associated with the commands. Table 3 shows the 
baseline characteristics of the whole study sample and 
the two groups.
Participants allocated to the cognitive therapy for 
command hallucinations + treatment as usual group 
received a mean of 19 sessions of cognitive therapy (SD 9, 
range 0–36), each lasting about 1 h. Adherence to 
cognitive therapy was excellent, with only 12 (12%) of 
98 participants not attending any sessions, and 79 (81%) 
completing the therapy (all manualised elements). 
Fidelity to the therapy model was assessed by supervisors 
EP and AM using the adherence scales with audio 
recordings. 17 (20%) of 86 participants in the cognitive 
therapy for command hallucinations + treatment as 
usual group were randomly selected and 
117 of 1500 therapy sessions were rated (8% of all sessions 
in the cognitive therapy for command hallucinations + 
treatment as usual group). 72 (62%) of 117 therapy 
sessions scored higher than the cutoﬀ  based on our 
ﬁ delity protocol (score ≥3 is acceptable use of cognitive 
therapy for command hallucinations).
55% of the participants in the treatment as usual group 
complied fully (VCS score 5) with treatment during the 
ﬁ rst 9 months after randomisation compared with 48% in 
the cognitive therapy for command hallucinations + 
treatment as usual group (table 4). In the 9 months after 
completion of cognitive therapy for command 
hallucinations + treatment as usual, 46% of the participants 
in the treatment as usual group complied fully compared 
with 28% of those in the cognitive therapy for command 
hallucinations + treatment as usual group (table 4).
The estimated parameters in the initial model included 
a main eﬀ ect of treatment and an eﬀ ect of treatment-by-
time interaction. The treatment-by-time interaction 
indicates how the rates of compliance in the two 
treatment groups diverge over time. At 9 months, the 
odds ratio was 0·74 (95% CI 0·40–1·39, p=0·353). At 
18 months, the odds ratio was 0·45 (0·23–0·88, 
p=0·021). Although both odds ratios are less than 1, 
there might be a discrepancy between the treatment 
eﬀ ects at the two follow-up timepoints. However, the 
treatment-by-time interaction (a measure of this 
discrepancy), with an estimated odds ratio of 0·54 
(0·27–1·1, p=0·091), was not signiﬁ cant and was 
therefore removed from the model. The resulting 
estimate of the treatment eﬀ ect, interpreted as the eﬀ ect 
that is common to both follow-up timepoints, was an 
odds ratio of 0·57 (0·33–0·98, p=0·042).
Examples Compliance Appeasement
Harm self (n=119) “Cut yourself”
“Drink bleach”
“Don’t take your medication”
Drinking bleach, cutting or slashing wrists, not taking 
medication and consequently becoming unwell, or 
walking in front of cars
Making superﬁ cial cuts; mentally rehearsing 
slashing wrists
Harm others (n=34) “Attack someone”
“Hurt your children”
“Smash him or her over the head”
Punching, hitting, and pushing people; hitting children, 
or beating up partner
Threatening to harm or attack other people; 
planning how to execute the attack
Kill self (n=42) “Take an overdose and kill yourself”
“Jump oﬀ  the bridge”
“Commit suicide”
Attempted suicide in response to commands by taking 
an overdose; tied an iron cord around neck; jumping in 
front of cars
Obtaining tablets and mentally rehearsing taking an 
overdose; visualising and planning committing 
suicide by jumping oﬀ  a bridge
Kill others (n=11) “Stab your ﬂ atmate or sister”
“Kill your husband or wife with a knife”
“Strangle him”
Attempting to strangle a woman; attacked and grabbed 
doctor by the throat
Mentally rehearsing killing people; threatening to 
kill people; buying a knife or axe and planning to kill 
someone
Destroy property (n=5) “Burn down the ﬂ at”
“Smash the windows”
“Trash it, destroy it”
Knocked things oﬀ  the shelves of a shop; hit the door of 
a car; smashed things in the house
Mentally rehearsing buying petrol and setting ﬁ re 
to the ﬂ at
Antisocial behaviour (n=9) “Start a ﬁ ght”
“Shout at them”
Shouting and swearing at other people; starting 
arguments with strangers or family
Respond to voices by saying “I will do it later”
Major social transgressions (n=14) “Steal from a shop”
“Rob these people”
Stealing from shops; running naked in the street Mentally rehearsing and planning how to steal from 
a shop
Day to day instructions (n=26) “Eat or don’t eat”
“Don’t wash”
Eat excessively or abstain from eating; not washing; 
not sleeping
Respond to voices by skipping some meals; 
appeasement by reassuring the voices that “I will do 
it later”
Threats (n=11) “We are out to get you”
“We will kill you”
Setting oneself on ﬁ re; taking an overdose Tie a rope around the neck and squeeze hard but 
then release
Participants might have had more than one command.
Table 2: Voice commands, compliance, and appeasement behaviour
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The independent data monitoring and ethics committee 
monitored all serious adverse events; the committee found 
no serious adverse events attributable to the therapy.
As with compliance, the treatment-by-time interaction 
was not signiﬁ cant and we therefore report the eﬀ ect of 
treatment for the two follow-up timepoints. For the VPD 
total, the estimated treatment eﬀ ect (adjusted mean 
outcome for the cognitive therapy for command 
hallucinations + treatment as usual group minus the 
corresponding mean for the treatment as usual group) 
common to both timepoints was –1·82 (95% CI 
–3·46 to –0·18, p=0·03). For the VPD power diﬀ erential 
item, the estimated treatment eﬀ ect for both timepoints 
was –0·52 (–0·849 to –0·185, p=0·002).
Treatment eﬀ ects for all other outcomes (PSYRATS 
total and distress, Calgary Depression, Beck Hopelessness 
and Beck Suicidal Ideation, BAVQ-R, and knowledge 
[omniscience] scale) were not signiﬁ cant (appendix). 
Notably, all secondary outcomes fell signiﬁ cantly over 
time, equally in both treatment groups (table 3; table 4).
No diﬀ erences were noted between groups at baseline 
or follow-up in the total amount of antipsychotics 
prescribed (olanzapine equivalents). 32 (16%) of 
197 participants received cognitive behaviour therapy as 
part of their routine care throughout the trial: 
17 (53%) of 32 in the treatment as usual group and 
15 (47%) in the cognitive therapy for command 
hallucinations + treatment as usual group (not 
concurrently with cognitive therapy for command 
hallucinations). There was no diﬀ erence between the 
groups in baseline or follow-up PANSS total or subscale 
scores (table3; table 4).
Discussion
By 18 months’ follow-up, 46% of the participants in the 
treatment as usual group had at least one episode of 
full compliance compared with 28% in the cognitive 
therapy for command hallucinations + treatment as 
usual group (table 4). Hence, the cognitive therapy for 
command hallucinations + treatment as usual group 
Whole sample
(n=197)
Cognitive therapy for command 
hallucinations + treatment as usual 
group (n=98)
Treatment as usual group
(n=99)
Age (years) 37·4 (12·1; 16–64) 38·8 (12·2; 16–63) 35·9 (11·9; 17–64)
Age at onset (years) 22·14 (10·56; 5–63), n=178 21·80 (10·27; 5–57) 22·48 (10·89; 11–63)
Sex, male:female 113:84 61:37 52:47
VPD total 26·95 (5·05; 9–35), n=191 26·54 (5·45; 9–35), n=95 27·36 (4·62; 13–35), n=96
VPD power 3·92 (1·10; 1–5), n=195 3·87 (1·18; 1–5), n=97 3·98 (1·03; 1–5), n=98
PANSS positive 19·38 (4·86; 10–33), n=197 19·11 (4·94; 11–32), n=98 19·64 (4·79; 10–33), n=99
PANSS hallucinations 5·28 (1·12; 2–7), n=197 5·21 (1·18; 2–7), n=98 5·34 (1·05; 2–7), n=99
PANSS delusions 3·73 (1·50; 1–7), n=197 3·69 (1·67; 1–7), n=98 3·77 (1·33; 1–7), n=99
PANSS negative 16·02 (6·29; 7–34), n=195 15·86 (6·30; 7–33), n=97 16·18 (6·31; 7–34), n=98
PANSS general 36·37 (8·60; 17–71), n=195 35·78 (8·83; 17–61), n=97 36·96 (8·38; 20–71), n=98
PANSS total 71·73 (16·56; 38–132), n=195 70·74 (17·11; 38–121), n=97 72·71 (16·02; 39–132), n=98
PSYRATS hallucinations (total) 32·63 (4·40; 18–41),n=194 32·27 (4·49; 18–41), n=95 32·97 (4·31; 21–41), n=99
PSYRATS distress (amount) 3·22 (0·85; 0–4), n=196 3·22 (0·83; 1–4), n=97 3·22 (0·87; 0–4), n=99
PSYRATS frequency 2·94 (1·21; 0–4), n=197 2·98 (1·22; 0–4), n=98 2·91 (1·21; 0–4), n=99
PSYRATS negative content (amount) 3·37 (0·78; 0–4), n=196 3·41 (0·81; 0–4), n=97 3·32 (0·74; 0–4), n=99
Calgary Depression 12·09 (6·01; 0–27), n=197 12·44 (6·33; 0–27), n=98 11·75 (5·68; 0–26), n=99
Beck Hopelessness 10·72 (5·39; 1–20), n=193 11·05 (5·33; 1–19), n=96 10·39 (5·46; 1–20), n=97
Beck Suicide Ideation 9·91 (9·37; 0–34), n=196 10·59 (9·64; 0–34), n=97 9·24 (9·10; 0–28), n=99
Personal Knowledge Questionnaire 10·99 (3·22; 1–15), n= 197 10·29 (3·32; 2–15), n=98 10·90 (3·10; 1–15), n=99
BAVQ-R malevolence 13·05 (4·33; 2–18), n=197 12·93 (4·46; 2–18), n=98 13·17 (4·22; 2–18), n=99
BAVQ-R benevolence 3·37 (3·99; 0–15), n=196 3·22 (3·82; 0–14), n=97 3·52 (4·16; 0–15), n=99
BAVQ-R omnipotence 13·49 (3·75; 0–18), n= 197 13·23 (3·77; 0–18), n=98 13·74 (3·72; 3–18), n=99
BAVQ-R total resistance 21·38 (4·86; 5–27), n=197 21·29 (5·12; 5–27), n=98 21·47 (4·60; 10–27), n=99
BAVQ-R emotional resistance 9·85 (2·30; 0–12), n=197 9·48 (2·48; 1–12), n=98 10·22 (2·06; 4–12), n=99
BAVQ-R behavioural resistance 11·53 (3·60; 0–15), n=197 11·81 (3·63; 2–15), n=98 11·25 (3·57; 0–15), n=99
BAVQ-R total engagement 5·06 (4·92; 0–21), n=197 4·87 (4·58; 0–19), n=98 5·25 (5·25; 0–21), n=99
BAVQ-R emotional engagement 1·99 (2·84; 0–12), n=197 1·82 (2·57; 0–12), n=98 2·16 (3·08; 0–11), n=99
BAVQ-R behavioural engagement 3·07 (2·97; 0–12), n=197 3·05 (2·84; 0–11), n=98 3·09 (2·92; 0–12), n=99
Data are mean (SD; range), unless otherwise indicated. Some scales have missing data and numbers are provided to indicate sample with complete data. VPD=Voice Power 
Diﬀ erential. PANSS=Positive and Negative Syndrome Scale. PSYRATS=Psychotic Symptoms Rating Scales. BAVQ-R=Beliefs About Voices Questionnaire-Revised. 
Table 3: Baseline characteristics of participants
See Online for appendix
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had a large, signiﬁ cant, and clinically meaningful 
reduction in the rate of compliance compared with the 
treatment as usual group (odds ratio 0·45). The odds 
ratio of the combined treatment eﬀ ect at both follow-up 
timepoints was 0·57. This eﬀ ect was matched by a 
change in the singular focus of the intervention: the 
voices’ perceived power to deliver a supposed threat to 
the individual (strictly the power diﬀ erence between 
the voices’ ability to deliver the threat and the voice 
hearer’s ability to withstand and mitigate the threat). In 
accord with our model, changes in power might have 
mediated change in compliance. This outcome requires 
a complex analysis, which we will present in future 
papers alongside the  results of a health-economic 
analysis. We believe that the results of this trial 
represent an important advance in the treatment of 
individuals with a high risk of committing harm to 
themselves or others. Reducing risk in those who have 
previously acted on their psychotic symptoms has not 
yet proved possible, other than ensuring that the best 
evidence-based treatment is provided and, as a last 
resort, the use of compulsory detention, which has 
been steadily rising in the UK and across Europe.26
In accord with the ﬁ ndings from our pilot study,16 no 
treatment eﬀ ect was noted for psychotic symptoms, 
including hallucinations. Unlike the pilot study, 
however, there was no eﬀ ect of cognitive therapy for 
command hallucinations on distress linked to voices or 
on depression; in the pilot study, these changes were 
lost at follow-up and the results of this trial conﬁ rm 
absence of eﬀ ect. Importantly, most of the symptoms 
measured in the current study fell signiﬁ cantly over 
time in both groups (as in the pilot study), probably 
indicating that the sample was identiﬁ ed at baseline at 
the peak of compliance and distress. In the treatment as 
usual group, despite improvement in symptoms and 
voice frequency with time, participants showed a much 
higher rate of compliance, with a fairly unchanged 
appraisal of the voices’ power, emphasising the 
importance of this appraisal. The eﬀ ect of cognitive 
9 months 18 months
Cognitive therapy for command 
hallucinations + treatment as usual 
group (n=98)
Treatment as usu al group 
(n=99)
Cognitive therapy for command 
hallucinations + treatment as usual 
group (n=98)
Treatment as usual group 
(n=99)
Full compliance 41/85 (48%) 49/89 (55%) 22/79 (28%) 39/85 (46%)
VPD total 21·31 (5·86; 7–33), n=87 23·98 (6·41; 11–35), n=85 22·39 (6·21; 9–34), n=75 23·42 (6·88; 7–35), n=81
VPD power 2·80 (1·18; 1–5), n=87 3·34 (1·36; 1–5), n=86 2·82 (1·29; 1–5), n=76 3·20 (1·42; 1–5), n=81
PSYRATS total 29·10 (7·57; 0–42), n=82 28·05 (8·55; 0–40), n=84 28·63 (5·93; 7–38), n=75 28·00 (8·88; 0–41), n=76
PSYRATS distress 2·83 (1·26; 0–4), n=82 2·52 (1·49; 0–4), n=84 2·6 (1·24; 0–4), n=75 2·70 (1·39; 0–4), n=76
PSYRATS frequency 2·49 (1·44; 0–4), n=85 2·42 (1·5; 0–4), n=89 2·39 (1·32; 0–4), n=76 2·23 (1·59; 0–4), n=82
PSYRATS negative content (amount) 3·06 (1·17; 0–4), n=83 2·88 (1·30; 0–4), n=85 3·09 (1·11; 0–4), n=75 3·10 (1·18; 0–4), n=77
PANSS positive 16·06 (4·53; 7–27), n=86 17·85 (5·51; 7–35), n=88 16·96 (5·32; 7–32), n=78 17·30(5·78; 7–35), n=83
PANSS negative 12·94 (5·22; 7–33), n=86 13·45 (4·97; 7–26), n=88 13·33 (5·47; 7–31), n=78 12·96 (4·48; 7–25), n=83
PANSS hallucinations 4·36 (1·71; 1–7), n=86 4·69 (1·59; 1–7), n=88 4·42 (1·55; 1–7), n=78 4·28 (1·62; 1–7), n=83
PANSS delusions 3·13 (1·50; 1–6), n=86 3·43 (1·42; 1–7), n=88 3·18 (1·49; 1–7), n=78 3·28 (1·60; 1–6), n=83
PANSS general 30·85 (8·36; 16–59), n=86 32·64 (9·10; 16–57), n=88 31·22 (8·40; 16–56), n=78 32·73 (9·36; 17–57), n=83
PANSS total 59·85 (14·24; 30–98), n=86 63·94 (16·26; 33–111), n=88 61·51 (15·46; 31–101), n=78 63·00 (16·92; 32–107), n=83
Calgary depression scale 8·77 (6·04; 0–24), n=86 8·76 (6·24; 0–25), n=87 7·79 (6·33; 0–23), n=78 7·36 (4·97; 0–20), n=83
Beck hopelessness scale 8·17 (5·01; 1–19), n=81 8·72 (5·62; 1–19), n=83 8·77 (5·09; 1–19), n=77 8·31 (5·58; 1–20), n=80
Beck Scale for Suicide Ideation 6·05 (9·11; 0–34), n=85 5·88 (8·74; 0–27), n=86 4·35 (6·98; 0–28), n=77 5·30 (8·22; 0–27), n=79
Personal Knowledge Questionnaire 10·15 (3·40; 0–15), n= 86 9·58 (3·74; 0–15), n= 86 10·51 (3·41; 0–15), n=75 10·38 (3·98; 0–15), n=79
BAVQ–R malevolence 10·60 (5·15; 0–18), n=87 11·41 (4·93; 0–18), n=86 11·05 (5·38; 0–18), n=75 11·65 (5·22; 0–18), n=79
BAVQ–R benevolence 3·18 (4·52; 0–17), n=87 3·28 (4·47; 0–18), n=86 2·77 (3·75; 0–13), n=74 2·86 (4·06; 0–15), n=79
BAVQ–R omnipotence 10·29 (4·46; 0–18), n=87 11·38 (4·85; 0–18), n=86 10·03 (5·07; 0–18), n=74 11·23 (4·82; 0–18), n=79
BAVQ–R total resistance 20·41 (5·99; 0–27), n=86 19·95 (6·09; 2–27), n=86 20·27 (5·61; 2–27), n=73 20·95 (5·85; 2–27), n=78
BAVQ–R emotional resistance 8·77 (2·95; 0–12), n=86 8·83 (3·09; 0–12), n=86 8·49 (3·38; 0–12), n=73 9·08 (3·30; 0–12), n=79
BAVQ–R behavioural resistance 11·64 (3·87; 0–15), n=86 11·13 (3·97; 0–15), n=86 11·78 (3·72; 0–15), n=73 11·90 (3·64; 0–15), n=78
BAVQ–R total engagement 4·27 (5·20; 0–23), n=86 4·70 (5·28; 0–22), n=86 4·05 (5·60; 0–17), n=73 4·23 (5·24; 0–24), n=78
BAVQ–R emotional engagement 1·80 (3·12; 0–12), n=86 2·27 (3·15; 0–12), n=86 1·70 (2·61; 0–11), n=73 2·01 (3·27; 0–12), n=79
BAVQ–R behavioural engagement 2·47 (2·82; 0–11), n=86 2·43 (2·66; 0–11), n=86 2·36 (2·91; 0–11), n=73 2·19 (2·87; 0–12), n=78
Data are n/N (%) or mean (SD; range), unless otherwise indicated. Higher scores indicate poorer outcome. Some scales have missing data and numbers are provided to indicate sample with complete data. 
VPD=Voice Power Diﬀ erential. PSYRATS=Psychotic Symptoms Rating Scales. PANSS=Positive and Negative Syndrome Scale. BAVQ-R=Beliefs About Voices Questionnaire-Revised.
Table 4: Primary and secondary outcomes at 9 months and 18 months
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therapy for command hallucinations seemed greater at 
18 months than at 9 months; however, we should be 
cautious in coming to this conclusion because the 
analyses (testing for the time-by-treatment interaction) 
showed that the diﬀ erence in the treatment eﬀ ects at 
9 months and 18 months was not signiﬁ cant. 
Nevertheless, the eﬀ ect at 9 months was not signiﬁ cant, 
suggesting that cognitive therapy for command 
hallucinations might have had a delayed eﬀ ect. This 
explanation is plausible because the intervention was 
delivered slowly and steadily over 9 months to vulnerable 
participants; thus, participants might have been more 
compliant during this period, before the intervention 
had time to fully take eﬀ ect.
The results of the COMMAND trial conﬁ rm the size 
and focal nature of the eﬀ ect of cognitive therapy for 
command hallucinations on power and compliance, 
ﬁ rst reported in our pilot trial. Cognitive therapy for 
command hallucinations was acceptable to clients, as 
shown by the high rate (>80%) of completion of 
treatment, among the highest reported for cognitive 
behaviour therapy (or indeed other treatment) for 
psychosis. Cognitive therapy for command hallu-
cinations was not designed to be a panacea for all 
diﬃ  culties linked to psychosis and commanding voices, 
but to target this one key appraisal (power diﬀ erential) 
and behaviour (full compliance) for which it appears to 
be successful. At the end of therapy, many participants 
remained signiﬁ cantly depressed and continued to be 
distressed by their voices. Other interventions will be 
needed to address these (eg, conventional cognitive 
behaviour therapy for psychosis). Our recent 
longitudinal study of voice compliance27 showed that in 
addition to voice power, impulsivity, but not anger, was a 
predictor, suggesting other potential intervention 
targets to improve outcome with cognitive therapy for 
command hallucinations (panel).
So far, COMMAND is the largest trial of treatment for 
the high-risk group of individuals who are traditionally 
diﬃ  cult to study and to follow up; it is also one of the 
few trials focusing on risk of serious harm in psychosis, 
and the only such trial with commanding hallucinations. 
The high rate of consent to randomisation and level of 
completed follow-up (both >80%) assures the validity 
and generalisability of the ﬁ ndings (the high rate of 
consent probably indicates treatment resistance and 
harm linked to this symptom). The primary outcome, 
the presence of any episode of full compliance in the 
follow-up, was a stringent test of the hypothesis. In 
situations in which the frequency of full compliance 
might have fallen, the rating was given as full 
compliance, potentially underestimating the treatment 
eﬀ ect; for example, there were many instances in which 
major episodes of self-harm fell sharply (eg, from 
weekly to once in 9 months) but this beneﬁ t was not 
indicated in the outcome. This limitation will need to be 
addressed in future work. Adherence to treatment was 
excellent; however, the rated level of ﬁ delity to cognitive 
therapy for command hallucinations, based on a 
random set of recordings, was good (62%), but not as 
high as expected. There were two broad reasons for this 
limitation. First, therapists strayed from pure cognitive 
therapy for command hallucinations to include broader 
cognitive behaviour therapy, probably because of the 
complexity of the clients. Second, clients were often 
distressed by the voices within sessions, requiring 
therapists to spend much time encouraging 
communication and talking about neutral topics, which 
could not be rated like cognitive therapy for command 
Panel: Research in context
Systematic review
Two systematic reviews of cognitive behaviour therapy for 
psychosis have been reported.28,29 The results of the ﬁ rst 
systematic review28 showed small to moderate eﬀ ect sizes of 
therapy on positive psychosis symptoms. The results of the 
second,29 a Cochrane review, of the comparison of cognitive 
behaviour therapy with a control psychosocial intervention, 
showed that deﬁ nitive conclusions could not be drawn 
because of an insuﬃ  cient number of trials, but there was some 
evidence of equivalence. The results of a rigorous trial in The 
Lancet30 showed cognitive behaviour therapy to be eﬀ ective in 
participants who had refused medication (all previous trials 
were of participants who were on medication). The results of a 
systematic review,28 which included our pilot trial16 with the 
largest eﬀ ect size, showed substantial heterogeneity, 
indicating that cognitive behaviour therapy might have better 
eﬀ ectiveness in some contexts. The recent updated guidance 
from the National Institute for Health and Care Excellence for 
schizophrenia15 lends support to this view.
Interpretation
To the best of our knowledge, COMMAND is the ﬁ rst 
large-scale trial to test the eﬀ ect of cognitive behaviour 
therapy on harmful behaviour, rather than overall psychosis 
symptoms. The results are strong evidence of substantial 
reductions in harmful compliance. This outcome must be 
viewed in the context of the high-risk criteria we used. 
According to our results, individuals showing evidence of 
recent harmful compliance (<9 months) are at high risk of 
further compliance within 18 months (46%). Whether 
individuals who hear commands, but have yet to comply or 
do so infrequently, can be prevented from future compliance 
is not known. Because the cognitive behaviour therapy we 
used seems to be highly acceptable and most individuals 
completed the treatment, it might have wider application in 
some troublesome auditory hallucinations. Results of 
COMMAND resolve the uncertainty about the eﬀ ectiveness of 
cognitive behaviour therapy in reducing harm from 
commanding hallucinations, and suggest that the next 
generation of trials will be more eﬀ ective if they are theory 
driven and target behaviour or distress, rather than psychosis 
symptoms. 
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hallucinations. These ﬁ delity issues will be addressed in 
further papers drawing on the qualitative aspect of the 
trial protocol. The possibility of therapist eﬀ ects needs 
to be acknowledged; the contribution of non-protocol-
based therapeutic eﬀ ects might create clustering within 
the data and therefore lead to imprecision in the actual 
eﬀ ects. However, the beneﬁ ts of cognitive therapy for 
command hallucinations might be due to qualities of 
some therapists that are not captured in the manualised 
treatment, which may weaken the eﬀ ect of cognitive 
therapy for command hallucinations in routine care.
Cognitive behaviour therapy for psychosis has become 
a complex package and recent meta-analyses have 
shown that its eﬀ ect is smaller than suggested by the 
results of initial trials. Trials of the comparison of 
cognitive behaviour therapy with treatment as usual 
might have limitations due to poor treatment as usual, 
as reported by the Schizophrenia Commission; however, 
as we report here, treatment as usual was characterised 
by a very high level of treatment and service contact 
with the participants due to the concern about the risks. 
The absence of an active control intervention raises the 
possibility that a non-speciﬁ c aspect of cognitive therapy 
for command hallucinations (eg, extra treatment time) 
might account for some or all of the eﬀ ect size. If this 
were the case, we would have expected non-speciﬁ c 
changes in many outcome domains; however, as 
predicted, we noted changes in perceived voice power 
and compliance, but not psychosis or other symptoms. 
Another, equally credible therapy might have achieved 
the same outcome. We decided ﬁ rst to establish whether 
this theoretically informed intervention could have a 
clinically signiﬁ cant eﬀ ect on treatment-refractory and 
high-risk participants. The results of the COMMAND 
trial now open the way for more complex and expensive 
trials to resolve these questions. We have previously 
argued,31 however, that the next generation of trials of 
cognitive behaviour therapy should move away from the 
conventional goal of reducing psychotic symptoms in 
participants to focus on the core goal of cognitive 
behaviour therapy—ie, changing aﬀ ect and behaviour—
with theoretically informed and more focused 
interventions. In this respect COMMAND might be 
considered a model of the next generation of cognitive 
behaviour therapy trials for psychosis.
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